Thursday 16 October, 2025
Goal: There is a growing need to understand the link between obesity and type 2 diabetes. An important link is…
Read moreoral presentation
Stochastic differential equations in NONMEM
Thursday 16 October, 2025
Zipped PDF of presentation Objectives: The objective of the present analysis is to explore the use of stochastic differential equations…
Read moreA Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta
Thursday 16 October, 2025
Objectives: The objective was to develop a Mechanism-Based PK/PD model that predicts the time courses of hematological responses after administration…
Read morePharmacokinetic-Pharmacodynamic Modelling of QT-Prolongation following Deliberate Self-Poisonings with Citalopram
Thursday 16 October, 2025
PDF of presentation Objectives: Â Pharmacokinetic-pharmacodynamic (PKPD) models describing the time-course of QT-prolongation after overdoses would be valuable to predict the…
Read moreResisting population PK, the story of P-gp inhibition and co-administered chemotherapy.
Thursday 16 October, 2025
PDF of presentation Multidrug resistance is an ongoing barrier for the effective treatment of cancer patients. P-gp is a significant…
Read moreProspective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high-dose chemotherapy.
Thursday 16 October, 2025
PDF of presentation Objectives: High-dose chemotherapy with cyclophosphamide (CP), thiotepa (TT) and carboplatin (CA) (CTC) can be complicated by the…
Read morePopulation Pharmacokinetics of Intravenous Busulfan in Children
Thursday 16 October, 2025
Background: High-dose busulfan (bu) is an important part of many conditioning regimens before autologous or allogeneic bone marrow transplantation in…
Read moreSub-group Nonsense. Problems In Interpreting And Considering Covariates In Evaluation
Thursday 16 October, 2025
Sub-group analysis is driven by our desire as doctors to treat individuals as individuals not as groups – in which…
Read moreThe Value of Priors and Prior Uncertainty in Clinical Trial Simulation: Case Study with Actinomycin-D in Children with Cancer
Thursday 16 October, 2025
PDF of presentation Introduction: Actinomycin–D (AMD) is an antineoplastic agent used for the treatment of childhood cancers since the 1960’s….
Read moreAssessment of the Contribution of Components in a Combination Drug Product Using Population PK Modeling
Thursday 16 October, 2025
Drug A has a highly variable pharmacokinetics (PK) with a short half-life, nonlinear at high doses, inactivated by metabolism, and…
Read more